1. Dunn,B.K. and Ford,L.G. ( 2001 ) From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J. , 7 , 144 –157.
2. Lubet,R.A., Steele,V.E., DeCoster,R., Bowden,C., You,M., Juliana,M.M., Eto,I., Kelloff,G.J. and Grubbs,C.J. ( 1998 ) Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model. Carcinogenesis , 19 , 1345 –1351.
3. Pappas,S.G. and Jordon,V.C. ( 2002 ) Chemoprevention of breast cancer: current and future prospects. Cancer Metastasis Rev. , 21 , 311 –321.
4. Gottardis,M.M., Bischoff,E.D., Shirley,M.A., Wagoner,M.A., Lamph,W.W. and Heyman,R.A. ( 1996 ) Chemoprevention of mammary carcinoma by LGD 1069 (Targretin): an RXR selective ligand. Cancer Res. , 56 , 5566 –5570.
5. Suh,N., Lamph,W.W., Glasebrook,A.L., Grese,T.A., Palkowitz,A.D., Williams,C.R., Risingson,R., Farris,M.R., Heyman,R.A. and Sporn M.B. ( 2002 ) Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. Clin. Cancer Res. , 8 , 3270 –3275.